ABRAM Therapeutics Limited
- Biotech or pharma, therapeutic R&D
ABRAM Therapeutics Limited (ABRAM), has been admitted into Roche Accelerator April 1, 2025. We have successfully concluded the pre-clinical PCC experiment for a pioneering asset aimed at transient arginine depletion. We are seeking an investment of USD 8 million to finalize the generation of first-in-human weight loss data at 4 weeks and 12 weeks by the end of 2026.
Address
OtherHong Kong
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}